Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/348850
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE ESTADUAL DE CAMPINASpt_BR
dc.contributor.authorunicampModolo, Fabiana Duarte Mendes e-
dc.contributor.authorunicampModolo, Fabiana Duarte Mendes e-
dc.contributor.authorunicampMendes, Gustavo Duarte-
dc.typeArtigopt_BR
dc.titleCiprofibrate quantification in human plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry for pharmacokinetic studiespt_BR
dc.contributor.authorMendes, Fabiana D.-
dc.contributor.authorChen, Lu Shi-
dc.contributor.authorBorges, André-
dc.contributor.authorBabadópulos, Tainah-
dc.contributor.authorIlha, Jaime O.-
dc.contributor.authorAlkharfy, Khalid M.-
dc.contributor.authorMendes, Gustavo D.-
dc.contributor.authorDe Nucci, Gilberto-
dc.subjectFarmacocinéticapt_BR
dc.subject.otherlanguagePharmacokineticspt_BR
dc.description.abstractA rapid, sensitive and specific method for quantifying ciprofibrate in human plasma using bezafibrate as the internal standard (IS) is described. The sample was acidified prior extraction with formic acid (88%). The analyte and the IS were extracted from plasma by liquid–liquid extraction using an organic solvent (diethyl ether/dichloromethane 70/30 (v/v)). The extracts were analyzed by high performance liquid chromatography coupled with electrospray tandem mass spectrometry (HPLC–MS/MS). Chromatography was performed using Genesis C18 4 μm analytical column (4.6 × 150 mm i.d.) and a mobile phase consisting of acetonitrile/water (70/30, v/v) and 1 mM acetic acid. The method had a chromatographic run time of 3.4 min and a linear calibration curve over the range 0.1–60 μg/mL (r > 0.99). The limit of quantification was 0.1 μg/mL. The intra- and interday accuracy and precision values of the assay were less than 13.5%. The stability tests indicated no significant degradation. The recovery of ciprofibrate was 81.2%, 73.3% and 76.2% for the 0.3, 5.0 and 48.0 ng/mL standard concentrations, respectively. For ciprofibrate, the optimized parameters of the declustering potential, collision energy and collision exit potential were −51 V, −16 eV and −5 V, respectively. The method was also validated without the use of the internal standard. This HPLC–MS/MS procedure was used to assess the bioequivalence of two ciprofibrate 100 mg tablet formulations in healthy volunteers of both sexes. The following pharmacokinetic parameters were obtained from the ciprofibrate plasma concentration vs. time curves: AUClast, AUC0–168 h, Cmax and Tmax. The geometric mean with corresponding 90% confidence interval (CI) for test/reference percent ratios were 93.80% (90% CI = 88.16–99.79%) for Cmax, 98.31% (90% CI = 94.91–101.83%) for AUClast and 97.67% (90% CI = 94.45–101.01%) for AUC0–168 h. Since the 90% CI for AUClast, AUC0–168 h and Cmax ratios were within the 80–125% interval proposed by the US FDA, it was concluded that ciprofibrate (Lipless® 100 mg tablet) formulation manufactured by Biolab Sanus Farmacêutica Ltda. is bioequivalent to the Oroxadin® (100 mg tablet) formulation for both the rate and the extent of absorptionpt_BR
dc.relation.ispartofJournal of chromatography B, analytical technologies in the biomedical and life sciencespt_BR
dc.relation.ispartofabbreviationJ. chromatogr. B, analyt. technol. biomed. life sci.pt_BR
dc.publisher.cityAmsterdam pt_BR
dc.publisher.countryPaíses Baixospt_BR
dc.publisherElsevierpt_BR
dc.date.issued2011-
dc.date.monthofcirculationAug.pt_BR
dc.language.isoengpt_BR
dc.description.volume879pt_BR
dc.description.issuenumber24pt_BR
dc.description.firstpage2361pt_BR
dc.description.lastpage2368pt_BR
dc.rightsFechadopt_BR
dc.sourceWOSpt_BR
dc.identifier.issn1570-0232pt_BR
dc.identifier.eissn1873-376Xpt_BR
dc.identifier.doi10.1016/j.jchromb.2011.05.055pt_BR
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S1570023211003722pt_BR
dc.date.available2020-09-08T16:00:28Z-
dc.date.accessioned2020-09-08T16:00:28Z-
dc.description.provenanceSubmitted by Susilene Barbosa da Silva (susilene@unicamp.br) on 2020-09-08T16:00:28Z No. of bitstreams: 0. Added 1 bitstream(s) on 2021-01-04T15:12:52Z : No. of bitstreams: 1 000294239800001.pdf: 857851 bytes, checksum: bad3e23a37239938b10cd91a4799508f (MD5)en
dc.description.provenanceMade available in DSpace on 2020-09-08T16:00:28Z (GMT). No. of bitstreams: 0 Previous issue date: 2011en
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/348850-
dc.contributor.departmentSem informaçãopt_BR
dc.contributor.departmentSem informaçãopt_BR
dc.contributor.departmentSem informaçãopt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.subject.keywordCiprofibratept_BR
dc.subject.keywordHealthy volunteerpt_BR
dc.subject.keywordPlasmapt_BR
dc.subject.keywordHPLC–MS/MSpt_BR
dc.identifier.source000294239800001pt_BR
dc.creator.orcidSem informaçãopt_BR
dc.creator.orcidSem informaçãopt_BR
dc.creator.orcidSem informaçãopt_BR
dc.type.formArtigopt_BR
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
000294239800001.pdf837.75 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.